Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Behind The NASH Leaders, Pursuers Already Anticipating Second-Wave Improvements

Executive Summary

Privately held Cirius and NGM and big pharma Bristol-Myers Squibb are in Phase II for NASH with programs also working to validate non-invasive biomarkers for diagnosis, prognosis and treatment impact.


Related Content

AstraZeneca's License Of Ionis NASH Candidate Illustrates Still Hot Competition
Cirius CEO Bob Baltera On Being In Hot Pursuit Of NASH
Boehringer Ingelheim Confident Of A Happier Ending In NASH Than HCV
Galectin Offers Subgroup Approach For Struggling NASH Candidate
Genfit May Be Gaining An Edge In NASH Race
Gilead Data Suggest Role For ACC Inhibition In NASH
Stealthy NGM And Bristol Emerge As Serious NASH Competitors
Cirius Suspects Insulin Resistance Is Underlying Key To NASH
Genfit Says Safety/Tolerability Will Give Elafibranor An Edge In NASH


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts